efalizumab (Raptiva)
efalizumab is an FDA-licensed reference biologic from Genentech, Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2003
Reference approved
Reference product
Raptiva efalizumab
Genentech, Inc.
- Approved
- Oct 27, 2003
- Marketing
- Disc
- Center
- CDER
- Patents
- None listed
Molecular structure
Experimental 3D structure for efalizumab from the RCSB Protein Data Bank (PDB 3EO9).
Interactive biological assembly from PDB entry 3EO9. Drag to rotate, scroll to zoom, and inspect the full atomic structure right here — no need to leave the page.
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for efalizumab, in chronological order.
Reference approval
Approval date of the reference efalizumab product.
22 yr 11 mo ago
Frequently asked questions
Are there biosimilars approved for efalizumab (Raptiva)?
No 351(k) biosimilars or interchangeable biosimilars referencing efalizumab are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.